Overview

An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

This is a double-blind, randomised, three period crossover phase 1 trial using automated 8-hour euglycemic clamps in healthy Japanese subjects. Each subject will be randomly allocated to one out of nine sequences to receive either three single doses of BioChaperone insulin lispro or one single dose of Humalog® and two single doses of BioChaperone insulin lispro on three separate dosing visits. The total trial maximum duration for a subject will be up to 10 weeks.

Phase:

Phase 1

Details

Lead Sponsor:

Adocia

Collaborator:

Eli Lilly and Company

Treatments:

Insulin
Insulin Lispro
Insulin, Globin Zinc